Introduction
============

In Latin America, almost 1 million cardiovascular deaths occur annually being coronary heart disease, stroke, and hypertension reported as the primary cause of death.[@suaa048-B1] In Venezuela, cardiovascular diseases are the primary cause of death mainly coronary heart disease, stroke, and heart failure.[@suaa048-B2] Hypertension is the principal risk factor for cardiovascular disease, accompanied by diabetes mellitus, obesity, lipid abnormalities, smoking, and low physical activity.

In the 2008 CARMELA study, in a representative population of 25- to 64-year-olds, the prevalence of hypertension for Venezuela was estimated to be 24.7%; diabetes mellitus was 6% and obesity measured by body mass index (BMI) was 25.1%.[@suaa048-B3] In contrast, in the MMM2017 campaign the percentage of current hypertension was 48.9% which was higher, than the American Continent (41%) or worldwide (34.9%) proportions. Diabetes was reported in 10.7% and obesity in 16.2% among 21 644 participants.[@suaa048-B4]

The aims of this version of the MMM campaign were to raise awareness of the importance of blood pressure (BP) in the Venezuelan population and enhance the quality of data and to compare data to previous MMM study.

Methods
=======

The protocol was approved by the ethics committee at Dean of Health Sciences of University Centro-Occidental Lisandro Alvarado, Venezuela. Sixty-one screening sites were distributed in eight regions and about four people were involved in collection of data for each site. The Venezuelan chain of pharmacies, FARMATODO, collaborated to share their branches including pharmacists and personnel properly trained to carry out the study during May and June 2018. Other small groups of subjects were included from universities and health centres.

A short questionnaire was filled in as published elsewhere.[@suaa048-B5] Measurements were then carried out including BP, height, and weight. Blood pressure was measured in the sitting position three times after resting for at least 5 min, 1 min apart. Blood pressure was taken from either arm, using validated oscillometric devices of different brands. Data were entered on paper forms and later transferred to spreadsheets and transmitted to the central MMM database.

Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg or on pharmacological treatment for hypertension. Weight and height were measured in all cases, and body mass index was calculated, using WHO classification. Analysis of data was carried out centrally by the global MMM project team using the method previously published, with multiple imputation performed based on global data[@suaa048-B5] to impute missing values of the second and third BP reading.

Results
=======

The number of participants included from Venezuela was 28 649 subjects with a mean age of 54.2 years (SD 15.1). More women were included (62.8%), the self-reported ethnicity was predominantly mixed (65.0%) followed by white (30.0%), and black (4.8%). 9.5% of participants reported having diabetes, 4.3% had a previous myocardial infarction, 2.4% had a previous stroke; and 8.7% were current smokers.

Blood pressure was measured three times in 99.3% of subjects. The average BP in 1st, 2nd, and 3rd readings were 125.9/77.1 mmHg, 123.7/75.9 mmHg, and 122.6/75.3 mmHg, respectively; the average of 2nd and 3rd readings was 123.4/75.9 mmHg. For analysis, the average of 2nd and 3rd readings were used.

After imputing the missing values in our dataset, 13 861 (48.4%) participants were estimated to have hypertension; 2415 (14.0%) of those not receiving antihypertensive treatment were found with elevated BP (unknown hypertensives) and 3854 (33.7%) of those receiving treatment had uncontrolled hypertension. The percentage of all hypertension that was controlled was 54.8.

Body mass index calculated for the total population was on average 25.2 (SD: 4.7) kg/m^2^. Of all, 14.2% were classified as obese and 32.6% as overweight; meanwhile 4.8% as underweight. After adjusting for age and sex (with an interaction) and anti-hypertensive medication, we found a strong association between BMI and BP. A participant that was considered overweight or obese was associated with higher SBP and DBP measurements than participants who were a healthy weight. Conversely, a participant that was underweight was associated with lower SBP and DBP measurements compared to participants with a healthy weight ([Supplementary material online, *Figure S1*](#sup1){ref-type="supplementary-material"}).

After adjustment for age and sex, significantly higher SBP and DBP were apparent in subjects who were receiving antihypertensive drug treatment compared with those not on such treatment. Only systolic BP was higher for subjects with self-reported diabetes or previous myocardial infarction compared with those without diabetes or a previous myocardial infarction. Participants who were current smokers were associated with lower SBP/DBP levels (−1.43 mmHg, 95% CI −2.18 to −069/0.45 mmHg, 95% CI −0.73 to −0.10), respectively than those who did not smoke. There was strong evidence (*P* \< 0.001) to suggest pregnant women had lower systolic and diastolic BPs \[−3.93, 95% CI −6.00 to −1.86) and −3.35, 95% CI −4.57 to −2.13) respectively\] ([Supplementary material online](#sup1){ref-type="supplementary-material"}, *Figures S2 and S3*).

Discussion
==========

The Venezuelan MMM2018 campaign included a sample of 28 649 subjects; the percentage of people with hypertension was 48.4% which was consistent with the previous campaign 2017 (48.9%), but higher than for the American Continent (40.4%) or worldwide (33.4%).[@suaa048-B5]

Of those individuals not receiving hypertension drug treatment, 14.0% were hypertensive in Venezuela, compared to 17.9% globally and 15.7% in the Americas.[@suaa048-B5] The proportion of participants with controlled hypertension was 54.8% compared to 43% and 33.2% for the Americas or worldwide data, respectively.[@suaa048-B5]

Obesity was prevalent in 14.2% of participants and 4.8% were underweight in the present campaign comparing to 16.0% and 4.1%, respectively of individuals included in the MMM2017 campaign.[@suaa048-B6] Carballo-Arias[@suaa048-B7] reported important changes in the economy, job situation, and health in Venezuela since 2006 and a recent *Lancet* editorial described how the humanitarian, economical, and health crisis is deteriorating.[@suaa048-B8] This may explain reductions in the prevalence of obesity in the Venezuelan population since obesity in the CARMELA study was reported in 25.1%.[@suaa048-B3]

In the present study, diabetes was present in 9.5% of individuals in contrast to 10.7% of cases reported last year.[@suaa048-B6]

The strongest factors on mean SBP in our study were: known hypertension (*P* \< 0.001), antihypertensive medication (*P* \< 0.001), diabetes (*P* \< 0.001), and previous myocardial infarction (*P* \< 0.028); on mean DBP only known hypertension and antihypertensive medication (*P* \< 0.001). In contrast, smoking was associated with lower SBP (*P* \< 0.001) and DBP (*P* \< 0.05). Alcohol intake once or more per week was associated with higher DBP (*P* \< 0.001) compared to no alcohol intake. Pregnancy was associated with lower SBP and DBP (*P* \< 0.001). In our case, both alcohol consumption and smoking appear to be reported less frequently than in previous studies.[@suaa048-B3]

Conclusions
===========

This cross-sectional survey in Venezuela allows us to state:

-   The proportion of hypertension in Venezuela compared to other MMM reports was higher than the worldwide or American averages.

-   Treated hypertensive subjects tend to have higher systolic and diastolic BP than non-treated and non-hypertensive subjects.

-   Obesity, previous myocardial infarction, and diabetes mainly influence higher systolic BP.

-   One-third of treated hypertensives were not controlled.
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